169 related articles for article (PubMed ID: 23588838)
1. Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo.
Kusano H; Ogasawara S; Akiba J; Nakayama M; Ueda K; Yano H
Int J Oncol; 2013 Jun; 42(6):1897-903. PubMed ID: 23588838
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo.
Yano H; Ogasawara S; Momosaki S; Akiba J; Kojiro S; Fukahori S; Ishizaki H; Kuratomi K; Basaki Y; Oie S; Kuwano M; Kojiro M
Liver Int; 2006 Oct; 26(8):964-75. PubMed ID: 16953837
[TBL] [Abstract][Full Text] [Related]
3. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Itokawa N; Atsukawa M; Tsubota A; Okubo T; Arai T; Nakagawa A; Kondo C; Iwakiri K
Int J Clin Oncol; 2016 Aug; 21(4):676-683. PubMed ID: 26701173
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.
Savić R; He X; Fiel I; Schuchman EH
PLoS One; 2013; 8(5):e65620. PubMed ID: 23724146
[TBL] [Abstract][Full Text] [Related]
5. Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
Yan Y; Wang L; He J; Liu P; Lv X; Zhang Y; Xu X; Zhang L; Zhang Y
Biomed Pharmacother; 2017 Apr; 88():395-402. PubMed ID: 28122304
[TBL] [Abstract][Full Text] [Related]
6. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
7. Effects of pegylated interferon α2b on metastasis of hepatocellular carcinoma.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T
J Surg Res; 2012 Jan; 172(1):95-101. PubMed ID: 20851413
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
Tan W; Zhu S; Cao J; Zhang L; Li W; Liu K; Zhong J; Shang C; Chen Y
Oncol Res; 2017 Nov; 25(9):1543-1553. PubMed ID: 28276313
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
Alsaied OA; Sangwan V; Banerjee S; Krosch TC; Chugh R; Saluja A; Vickers SM; Jensen EH
Surgery; 2014 Aug; 156(2):270-9. PubMed ID: 24953273
[TBL] [Abstract][Full Text] [Related]
10. A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.
Xu YY; Chen L; Wang GL; Zhou JM; Zhang YX; Wei YZ; Zhu YY; Qin J
BMC Cancer; 2013 Nov; 13():527. PubMed ID: 24195809
[TBL] [Abstract][Full Text] [Related]
11. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
Wan J; Liu T; Mei L; Li J; Gong K; Yu C; Li W
Br J Cancer; 2013 Jul; 109(2):342-50. PubMed ID: 23807172
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo.
Kusano H; Akiba J; Ogasawara S; Sanada S; Yasumoto M; Nakayama M; Ueda K; Ueda K; Kurita T; Todoroki K; Umeno Y; Nakashima O; Yano H
PLoS One; 2013; 8(12):e83195. PubMed ID: 24349459
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.
Kojiro S; Yano H; Ogasawara S; Momosaki S; Takemoto Y; Nishida N; Kojiro M
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):129-37. PubMed ID: 16706824
[TBL] [Abstract][Full Text] [Related]
16. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma.
Cheng Y; Luo R; Zheng H; Wang B; Liu Y; Liu D; Chen J; Xu W; Li A; Zhu Y
Oncotarget; 2017 Apr; 8(14):23265-23276. PubMed ID: 28423574
[TBL] [Abstract][Full Text] [Related]
18. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
Tsai JJ; Hsu FT; Pan PJ; Chen CW; Kuo YC
Anticancer Res; 2018 Apr; 38(4):2119-2125. PubMed ID: 29599330
[TBL] [Abstract][Full Text] [Related]
19. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
[TBL] [Abstract][Full Text] [Related]
20. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
Lu M; Fei Z; Zhang G
Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
